Immunohistochemical screening for oncogenic tyrosine kinase activation.
Tyrosine kinases causing the abnormal phosphorylation of intracellular proteins have been shown to contribute to oncogenic transformation in a number of human neoplasms. Immunohistological staining of routine biopsy sections for increased levels of phosphotyrosine may therefore provide a simple means of screening for tumours containing activated tyrosine kinases. In this study, monoclonal antibodies to phosphotyrosine were used to immunostain a cell line and tumour biopsies from lymphomas known to contain the activated anaplastic-lymphoma-kinase (ALK) tyrosine kinase. A range of normal and other neoplastic tissues were also immunostained for comparison. An anaplastic large cell lymphoma (ALCL) cell line carrying the (2;5) translocation, which creates the activated nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) tyrosine kinase, was strongly labelled. Routine tissue biopsies from five cases of ALK-positive ALCL were also strongly positive for phosphotyrosine. The characteristic granular cytoplasmic labelling pattern for phosphotyrosine observed in a B-cell lymphoma (expressing full length ALK kinase) was identical to that obtained using an ALK-specific antibody, thus confirming that labelling for phosphotyrosine in lymphoma cells reflects the presence of an activated kinase. When normal lymphoid tissues were stained, there was little or no labelling for phosphotyrosine, but stronger labelling was seen in other cells and tissues; for example, endothelial cells and some carcinoma samples. Whilst the strong labelling for phosphotyrosine observed in the lymphoma cells is due to the presence of activated ALK, the strong staining of some normal cells presumably represents physiologically active kinases and this should be taken into account when interpreting the immunostaining of non-lymphoid tumours. The simplicity of this method, however, means that it offers a new rapid approach to the screening of large numbers of tumours for the presence of aberrant tyrosine kinase activation, particularly if they arise from tissues which normally contain only background levels of phosphotyrosine.
Pulford
K
K
Leukaemia Research Fund Immunodiagnostics Unit, Nuffield Department of Clinical Biochemistry and Cellular Science, John Radcliffe Hospital, Oxford OX3 9DU, U.K. karen.pulford@cellular-science.ox.ac.uk
Delsol
G
G
Roncador
G
G
Biddolph
S
S
Jones
M
M
Mason
D Y
DY
D000911:Antibodies, Monoclonal / Q000276:immunology; D002051:Burkitt Lymphoma / Q000235:genetics; D002889:Chromosomes, Human, Pair 2; D002895:Chromosomes, Human, Pair 5; D004789:Enzyme Activation; D006801:Humans; D007124:Immunoenzyme Techniques; D008223:Lymphoma / Q000201:enzymology* / Q000235:genetics; D016403:Lymphoma, Large B-Cell, Diffuse / Q000201:enzymology / Q000235:genetics; D009363:Neoplasm Proteins / Q000378:metabolism*; D009857:Oncogenes; D019000:Phosphotyrosine / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D009363:Neoplasm Proteins; D019000:Phosphotyrosine; D011505:Protein-Tyrosine Kinases